GV and Novo-backed cardiovascular disease drug developer Verve priced an upscaled initial public offering above its range.

US-based cardiovascular disease therapy developer Verve Therapeutics is going public today in a $267m initial public offering representing exits for internet and technology group Alphabet and pharmaceutical firm Novo. The offering consists of just over 14 million shares issued on the Nasdaq Global Select Market, increased from 11.8 million and priced at $19.00 each, above…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.